Data Suggest Potential Feasibility of Ixazomib as Maintenance Therapy for Multiple Myeloma: Takeda

Takeda Pharmaceutical said that data from a PII clinical study demonstrated the potential feasibility of its investigational oral proteasome inhibitor ixazomib as a single-agent maintenance therapy in patients with multiple myeloma, with deepening responses and acceptable tolerability. The study, which...read more